Table III.
Relative values | ||||
---|---|---|---|---|
Treatment | MMP-2/β-actin | MMP-9/β-actin | Invasion cell number | Mobility optical density |
Control | 1.00±0.14 | 1.00±0.11 | 81.0±4.6 | 0.81±0.02 |
ClC-3 antisense | 0.61±0.17a | 0.64±0.25a | 42.0±4.4a | 0.58±0.13a |
Cisplatin | 0.59±0.05a | 0.63±0.14a | 48.3±2.5a | 0.42±0.07a |
Cisplatin+ClC-3 antisense | 0.59±0.27a | 0.29±0.09a,b | 12.7±5.1a,b | 0.31±0.11a,b |
Relative levels of MMP-2 and MMP-9 mRNA calculated from intensities of bands are shown in Fig. 5A. Relative numbers of invading cells calculated are shown in Fig. 5B. Treated cells were detached and resuspended in IMDM medium (5×105 cells/200 µl), and then added to the upper compartment of the invasion chamber without matrigel. The cells that invaded through the membrane of invasion chamber were measured with the MTT assay. Data show the means with standard deviations (SDs, bars) calculated from five separate experiments.
P<0.05 vs. control
P<0.05 vs. cisplatin by unpaired t-test. CLCN3, chloride voltage-gated channel 3; MMP, matrix metalloprotease.